Five Prime Therapeutics Announces the Departure of Dr. Sheila Gujrathi From its Board of Directors


SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the departure of Dr. Sheila Gujrathi from the company’s board of directors. Dr. Gujrathi has served as a board member of Five Prime since December 2015 and is stepping down from the board to focus on her role as President and Chief Executive Officer of Gossamer Bio….